Together, these data indicate that the deacetylase Sirt2 is a therapeutic target for the treatment of systemic fungal sepsis, and inhibitors of Sirt2 have the potential to be developed as drugs for the treatment of invasive fungal infection. This evidence concerns the gene SIRT2 and fungal infectious disease.